Form 144 - Report of proposed sale of securities:
SEC Accession No. 0002086827-25-000002
Filing Date
2025-09-22
Accepted
2025-09-22 19:18:18
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3291
  Complete submission text file 0002086827-25-000002.txt   4796
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39536 | Film No.: 251331303
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247
Business Address
Haque-Ahmed Rumana (Reporting) CIK: 0002086827 (see all company filings)

Type: 144